TR200100916T2 - - Google Patents

Info

Publication number
TR200100916T2
TR200100916T2 TR2001/00916T TR200100916T TR200100916T2 TR 200100916 T2 TR200100916 T2 TR 200100916T2 TR 2001/00916 T TR2001/00916 T TR 2001/00916T TR 200100916 T TR200100916 T TR 200100916T TR 200100916 T2 TR200100916 T2 TR 200100916T2
Authority
TR
Turkey
Application number
TR2001/00916T
Inventor
Davin@Clifford@Dillon
Susan@Louise@Harlocker
Jiang@Yuqiu
Jiangchun@Xu
JENNIFER@Lynn@Mitcham
Original Assignee
Corixa@@Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/116,134 external-priority patent/US7008772B1/en
Priority claimed from US09/115,453 external-priority patent/US6657056B2/en
Priority claimed from US09/159,812 external-priority patent/US6613872B1/en
Priority claimed from US09/232,880 external-priority patent/US7270980B2/en
Priority claimed from US09/232,149 external-priority patent/US6465611B1/en
Application filed by Corixa@@Corporation filed Critical Corixa@@Corporation
Publication of TR200100916T2 publication Critical patent/TR200100916T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TR2001/00916T 1998-07-14 1999-07-14 TR200100916T2 (2)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/116,134 US7008772B1 (en) 1997-02-25 1998-07-14 Compounds for immunodiagnosis of prostate cancer and methods for their use
US09/115,453 US6657056B2 (en) 1997-02-25 1998-07-14 Compounds for immunotherapy of prostate cancer and methods for their use
US15982298A 1998-09-23 1998-09-23
US09/159,812 US6613872B1 (en) 1997-02-25 1998-09-23 Compounds for immunotherapy of prostate cancer and methods for their use
US09/232,880 US7270980B2 (en) 1997-02-25 1999-01-15 Compounds for immunodiagnosis of prostate cancer and methods for their use
US09/232,149 US6465611B1 (en) 1997-02-25 1999-01-15 Compounds for immunotherapy of prostate cancer and methods for their use
US28894699A 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
TR200100916T2 true TR200100916T2 (2) 2002-06-21

Family

ID=27568734

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00916T TR200100916T2 (2) 1998-07-14 1999-07-14

Country Status (17)

Country Link
EP (2) EP1870466A3 (2)
JP (1) JP2002520054A (2)
KR (2) KR20070112860A (2)
CN (1) CN100419079C (2)
AU (2) AU762812B2 (2)
BR (1) BR9912007A (2)
CA (1) CA2334038A1 (2)
CZ (1) CZ2001149A3 (2)
HU (1) HUP0203035A3 (2)
IL (1) IL140845A0 (2)
NO (1) NO20010196L (2)
NZ (1) NZ509178A (2)
PL (1) PL200772B1 (2)
SA (1) SA99200618B1 (2)
TR (1) TR200100916T2 (2)
TW (2) TW200532020A (2)
WO (1) WO2000004149A2 (2)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) * 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
NZ514646A (en) * 1999-04-09 2005-04-29 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
CA2378846A1 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Prostase vaccine
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
AU7917200A (en) 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
DK1220913T3 (da) * 1999-10-05 2009-03-16 Agensys Inc G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
AU7753700A (en) * 1999-10-07 2001-05-10 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
EP1230364A2 (en) * 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
WO2001051633A2 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020150972A1 (en) * 2000-02-08 2002-10-17 Mary Faris 34P3D7: a tissue specific protein highly expressed in prostate cancer
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1311673A2 (en) * 2000-03-27 2003-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB0015736D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Biolog Vaccine
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
DK1889630T3 (da) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6821731B2 (en) 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2446788A1 (en) * 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
EP1578980A4 (en) * 2002-04-01 2013-01-02 Agensys Inc NUCLEIC ACID SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEIN HAVING NAME 213P1F11
DK1511768T3 (da) * 2002-06-11 2007-08-20 Glaxosmithkline Biolog Sa Immunogene sammensætninger
CA2487907A1 (en) * 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising a xenogenic prostate protein p501s
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2081027A4 (en) 2006-08-04 2009-09-23 Ajinomoto Kk METHOD FOR EVALUATING LUNG CANCER, LUNG CANCER EVALUATION DEVICE, LUNG CANCER EVALUATION METHOD, LUNG CANCER EVALUATION SYSTEM, LUNG CANCER EVALUATION PROGRAM AND RECORDING MEDIUM
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008075662A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
EP2096439A4 (en) 2006-12-21 2011-01-05 Ajinomoto Kk METHOD FOR ASSESSING COLORECTAL CARCINOMA, COLORECTAL CARCINOMA ASSESSMENT DEVICE, METHOD, SYSTEM, PROGRAM AND RECORDING MEDIUM
ES2376509T3 (es) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
KR100976218B1 (ko) 2008-05-26 2010-08-17 한국표준과학연구원 비행시간이차이온질량분광법을 이용한 질병의 진단 방법,질병 지표의 스크린 방법, 및 질병 지표
KR101821551B1 (ko) 2008-06-20 2018-01-25 아지노모토 가부시키가이샤 전립선 질환의 평가 방법
DK2837383T3 (en) * 2008-08-05 2017-03-20 Toray Industries Immunity Inducing Agent
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
US11137401B2 (en) 2008-08-05 2021-10-05 Toray Industries, Inc. Method for detecting cancer using CAPRIN-1 as a marker
KR20120036842A (ko) * 2009-05-12 2012-04-18 코닌클리케 필립스 일렉트로닉스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
CN102834113B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532365T3 (pl) 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
TR201808595T4 (tr) 2011-08-04 2018-07-23 Toray Industries Kanser hastalıklarının tedavisi ve/veya profilaksisi için farmasötik bileşim.
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
RU2611197C2 (ru) 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
IN2014KN01715A (2) 2012-02-21 2015-10-23 Toray Industries
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
CN104114583B (zh) 2012-02-21 2019-11-19 东丽株式会社 癌的治疗和/或预防用药物组合物
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
EP2832366B1 (en) 2012-03-30 2017-11-08 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP4541818A3 (en) * 2012-05-25 2025-07-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
JP6244911B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
ES2769831T3 (es) 2012-07-19 2020-06-29 Toray Industries Método para detectar cáncer
JP6283861B2 (ja) * 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
HUE042081T2 (hu) 2013-08-09 2019-06-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
EP4678748A2 (en) * 2015-12-21 2026-01-14 Novartis AG Compositions and methods for decreasing tau expression
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
IL263030B2 (en) 2016-05-16 2024-11-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
KR102748354B1 (ko) 2016-06-01 2024-12-31 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
EP3880827A4 (en) * 2018-11-07 2023-04-26 Akouos, Inc. COMPOSITIONS AND METHODS FOR INDUCING DIFFERENTIATION OF A HAIR CELL
CN111000858B (zh) * 2019-05-10 2021-04-09 常州市第二人民医院 Nupr1抑制剂在制备膀胱癌治疗药物中的用途
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CA3179694A1 (en) * 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
CN111968751B (zh) * 2020-06-29 2021-10-19 金电联行（北京）信息技术有限公司 一种使用多基线校正模型的传染病趋势预测方法与系统
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
CA3173408A1 (en) 2020-12-23 2022-06-30 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
EP4583841A1 (en) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
CA2030212A1 (en) * 1989-11-22 1991-05-23 Judson V. Edwards Peptides
AU5514396A (en) * 1995-04-28 1996-11-18 Takeda Chemical Industries Ltd. Cyclic pentapeptide lh-rh receptor antagonists
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
ES2248891T3 (es) * 1997-02-25 2006-03-16 Corixa Corporation Compuestos para inmunodiagnostico de cancer de prostata y metodos para su uso.
HUP0002095A3 (en) * 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US6130043A (en) * 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
EP1870466A2 (en) 2007-12-26
EP1870466A3 (en) 2008-03-19
IL140845A0 (en) 2002-02-10
CN1315998A (zh) 2001-10-03
HUP0203035A2 (hu) 2002-12-28
KR20010083111A (ko) 2001-08-31
WO2000004149A2 (en) 2000-01-27
BR9912007A (pt) 2002-01-29
KR20070112860A (ko) 2007-11-27
WO2000004149A3 (en) 2000-07-20
SA99200618B1 (ar) 2007-01-20
PL200772B1 (pl) 2009-02-27
AU2003248213A1 (en) 2003-10-30
TW200728465A (en) 2007-08-01
AU5314899A (en) 2000-02-07
HUP0203035A3 (en) 2007-12-28
CN100419079C (zh) 2008-09-17
NO20010196D0 (no) 2001-01-12
NO20010196L (no) 2001-03-12
CZ2001149A3 (cs) 2002-02-13
TW200532020A (en) 2005-10-01
NZ509178A (en) 2004-04-30
CA2334038A1 (en) 2000-01-27
PL346359A1 (en) 2002-02-11
AU762812B2 (en) 2003-07-03
JP2002520054A (ja) 2002-07-09
EP1097208A2 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
BE2014C048I2 (2)
BE2012C041I2 (2)
BRPI9914151B8 (2)
JP2001511599A5 (2)
BRPI9917863A2 (2)
BRPI9816295A2 (2)
IN184273B (2)
JP2639099C (2)
JP2540208C (2)
JP2508245Z (2)
GB199918442D0 (2)
CN3071793S (2)
CN3074547S (2)
CN3073964S (2)
CN3079458S (2)
CN3072760S (2)
CN3079455S (2)
CN3077989S (2)
CN3079025S (2)
BY4408C1 (2)
CN3079181S (2)
CN3077095S (2)
CN3074692S (2)
CN3074053S (2)
CN3079979S (2)